Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Researchers from the United States and AL 35294 report recent findings in HIV/AIDS
May 10th, 2006
HIV/AIDS research advances have been reported from the United States and AL 35294. Study 1: An HIV-1 recombinant canarypox vaccine is safe and immunogenic in infants of HIV-1-infected mothers. "Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1). "HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks," scientists in the United States report. According to D.C. Johnson and colleagues at Sinai Children's Hospital and...
Source: Vaccine Weekly (2006-05-10)
|
